Study the effect of mifepristone on fibroid and uterine volume
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20184958Keywords:
Fibroid volume, Mifepristone, Uterine volumeAbstract
Background: Fibroid is the most common benign tumour of the uterus affecting 20% of women of reproductive age group and is the most common indication for hysterectomy accounting for about 40% of all hysterectomies in premenopausal women. This study was undertaken to study the effect of Mifepristone, which is a progesterone receptor modulator with antagonistic action, on fibroid and uterine volume.
Methods: The study was conducted in the Department of Obstetrics and Gynaecology, Himalayan Institute of Medical Sciences, Swami Ram Nagar, Dehradun over a period of 12 months. A total of 40 patients were included in the study.
Results: Mean baseline fibroid volume decreased by 49.17% at 1 month and by 77.4% and 3months of treatment with Mifepristone. Mean baseline uterine volume decreased by 34.13% at 1 month, and further reduction by 58.3% at the end of treatment.
Conclusions: The study shows that there is a significant reduction in fibroid and uterine volume in patients treated with mifepristone.
References
Malhotra N, Kumar P, Malhotra J, Bora NM, Parul Mittal P, Jeffcoate’s Principle of Gynaecology. Tumour of corpus uteri, Jaypee Brothers medical publishers (P). Ltd. 2014, 8th Ed. p. 453.
Lesley L. Breech, John A. Rock. Leiomyomata uteri and myomectomy. TeLinde Operative Gynaecology, Lippincott Willians and Wilkins. 2008, 10th ed. P. 688
Whiteman MK, Hillis SD, Jamieson DJ, Morrow B, Podgornik MN, Brett KM et al. Inpatient hysterectomy surveillance in the United States, 2000-2004. Am J Obstet Gynecol. 2008;198(1):34-e1.
Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. American Journal of Obstetrics and Gynecology 1995;172(1):14-8.
Kapur A, Angomchanu R, Dey M. Efficacy of use of long-term, low-dose mifepristone for the treatment of fibroids. J Obstet Gynecol India. 2016;66(1):494-8
Das SS. Prospective Study on Low-Dose Mifepristone for the Treatment of Leiomyoma: A Hospital Based Study. International Archives of BioMedical and Clinical Research. 2018 Mar 21;4(1):104-6.
Bagaria M, Suneja A, Vaid NB, Guleria K, Mishra K. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust NZJ Obstet Gynaecol. 2009;49(1):77-83.
Mukherjee S, Chakraborty S. A study evaluating the effect of mifepristone (RU-486) for the treatment of leiomyomatauteri. Niger Med J 2011;52(3):150-2.
Jain D. Mifepristone therapy in symptomatic leiomyomata using a variable dose pattern with a favourable outcome. J Midlife Health. 2018;9(2):65.
Murphy AA, Morales AJ, Kettel LM, Yen SS. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil Steril. 1995;64(1):187-90.
Seth S, Goel N, Singh E, Mathur AS, Gupta G. Effect of mifepristone (25 mg) in treatment of uterine myoma in perimenopausal woman. J Midlife Health. 2013;4(1):22-6.
Eisinger SH, Fiscella J, Bonfiglio T, Meldrum S, Fiscella K. Open-label study of ultra-low-dose mifepristone for the treatment of uterine leiomyomata. Europe J Obstet Gynecol Reproduct Biol. 2009;146(2):215-8.
Yerushalmi GM, Gilboa Y, Jakobson-Setton A, Tadir Y, Goldchmit C, Katz D, et al. Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label study. Fertil Steril. 2014;101(2):496-500.
